Explore a selection of our essential drug information below, or:
Identification
- Summary
St. John's Wort is an herbal ingredient used in non-prescription therapeutic products for the short-term treatment of minor skin irritations, insomnia, depression, and anxiety.
- Generic Name
- St. John's Wort
- DrugBank Accession Number
- DB01323
- Background
Not Available
- Type
- Biotech
- Groups
- Approved, Investigational, Nutraceutical
- Synonyms
- Common st johnswort flowering top
- Common st. john's wort flowering top
- Common st. john's wort herb
- Common st. johnswort flowering top
- Guanyejinsitao
- Hyperici herba
- Hypericum nachitschevanicum flowering top
- Hypericum perforatum flowering top
- Hypoxis hemerocallidea root extract
- Klamath weed flowering top
- Klamathweed flowering top
- Saint johns wort
- St john's wort
- St Johns Wort
- St. john’s wort
- St. johns wort
- St. johnswort flowering top
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Anxiety ••• ••••• Treatment of Depression ••• ••••• Symptomatic treatment of Hot flashes ••• ••••• Treatment of Insomnia ••• ••••• Symptomatic treatment of Muscle pain ••• ••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The metabolism of 1,2-Benzodiazepine can be increased when combined with St. John's Wort. Abametapir The serum concentration of St. John's Wort can be increased when it is combined with Abametapir. Abatacept The metabolism of St. John's Wort can be increased when combined with Abatacept. Abemaciclib The serum concentration of Abemaciclib can be decreased when it is combined with St. John's Wort. Abiraterone The metabolism of Abiraterone can be increased when combined with St. John's Wort. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Ethical Herbals ST. John's Wort Tablet 300 mg/1 Oral Ashbury Research Corporation Not applicable Not applicable Canada 
Ethical Herbals ST. John's Wort Tablet 150 mg/1 Oral Ashbury Research Corporation Not applicable Not applicable Canada Felis Forte Capsules 425mg Capsule 425 mg / cap Oral Rhoxalpharma Inc Not applicable Not applicable Canada Felis Tablets 250mg Tablet 250 mg / tab Oral Rhoxalpharma Inc Not applicable Not applicable Canada ST. John's Wort Capsule 1500 mg Oral Sisu Inc. 1998-02-11 2007-07-20 Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Dynamiclear Rapid St. John's Wort (0.5 mg/1mL) + Calendula officinalis flower (0.5 mg/1mL) + Cupric sulfate pentahydrate (40 mg/1mL) Liquid Topical RX PHARMA-PACK, INC. 2019-02-06 2022-12-31 US 
Dynamiclear Rapid St. John's Wort (0.5 mg/1mL) + Calendula officinalis flower (0.5 mg/1mL) + Cupric sulfate pentahydrate (40 mg/1mL) Liquid Topical RX PHARMA-PACK, INC. 2019-02-06 2022-12-31 US Nite-caps St. John's Wort (20 mg / cap) + Hops (40 mg / cap) + Valerian (40 mg / cap) Capsule Oral Flora Manufacturing And Distributing Ltd. 1991-12-31 2002-09-10 Canada S. R. Formula St. John's Wort (200 mg / mL) + Valerian (133.2 mg / mL) Liquid Oral Morinda Canada 2002-01-14 2006-07-12 Canada
Categories
- ATC Codes
- N06AX25 — Hyperici herba
- Drug Categories
- Angiosperms
- Antidepressive Agents
- Antidepressive Agents Indicated for Depression
- Biological Products
- Central Nervous System Depressants
- Clusiaceae
- Complex Mixtures
- Cytochrome P-450 CYP2C19 Inducers
- Cytochrome P-450 CYP2C19 Inducers (strength unknown)
- Cytochrome P-450 CYP2C19 Substrates
- Cytochrome P-450 CYP2D6 Inhibitors
- Cytochrome P-450 CYP2D6 Inhibitors (weak)
- Cytochrome P-450 CYP3A Inducers
- Cytochrome P-450 CYP3A Inducers (strong)
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Inducers
- Cytochrome P-450 CYP3A4 Inducers (strong)
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 CYP3A4 Substrates (strength unknown)
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 Substrates
- Embryophyta
- Eukaryota
- Herbs and Natural Products
- Hyperglycemia-Associated Agents
- Nervous System
- P-glycoprotein inducers
- Pharmaceutical Preparations
- Plant Preparations
- Psychoanaleptics
- Rosanae
- Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
- Streptophyta
- Tracheophyta
- Viridiplantae
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- UFH8805FKA
- CAS number
- 84082-80-4
References
- Synthesis Reference
Trevor Percival Castor, Theodore Abraham Tyler, Richard Joseph Student, "Methods for making Hypericum fractions and St. John's Wort products." U.S. Patent US6291241, issued December, 1998.
US6291241- General References
- Lecrubier Y, Clerc G, Didi R, Kieser M: Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry. 2002 Aug;159(8):1361-6. [Article]
- Randlov C, Mehlsen J, Thomsen CF, Hedman C, von Fircks H, Winther K: The efficacy of St. John's Wort in patients with minor depressive symptoms or dysthymia--a double-blind placebo-controlled study. Phytomedicine. 2006 Mar;13(4):215-21. Epub 2006 Jan 19. [Article]
- Authors unspecified: Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002 Apr 10;287(14):1807-14. [Article]
- External Links
- PubChem Substance
- 46507869
- 1310069
- PharmGKB
- PA164924486
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Hypericum_perforatum
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Completed Not Available Drug Drug Interaction (DDI) 2 somestatus stop reason just information to hide Not Available Completed Not Available Major Depressive Disorder (MDD) 1 somestatus stop reason just information to hide Not Available Completed Treatment Contraception 1 somestatus stop reason just information to hide Not Available Completed Treatment Depression 1 somestatus stop reason just information to hide Not Available Completed Treatment Major Depressive Disorder (MDD) 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Guna Inc.
- Pekana Naturheilmittel GmbH
- Weleda Inc.
- Dosage Forms
Form Route Strength Liquid Topical Tablet Oral 900 mg / tab Tablet Oral 150 mg/1 Tablet Oral 300 mg/1 Tablet Oral 300 mg Capsule Oral 425 mg / cap Tablet Oral 250 mg / tab Tablet Oral 180 mg / tab Tablet Oral 300 mg / tab Tablet, coated Capsule Oral Tablet Oral 1500 mg / tab Tablet, coated 300 MG Tablet, film coated 300 MG Liquid Oral Capsule Oral 1050 mg Capsule Oral 1500 mg / cap Capsule Oral 1500 mg Capsule Oral 300 mg / cap Capsule Oral 750 mg / cap Tablet Oral 500 mg Liquid Oral 1000 mg / mL Capsule Oral 1045 mg / cap Capsule Oral 1320 mg / cap Liquid Oral 1 g / 1 mL Capsule Oral 300 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- SubstrateInducerActivator
- General Function
- A cytochrome P450 monooxygenase involved in the metabolism of sterols, steroid hormones, retinoids and fatty acids (PubMed:10681376, PubMed:11093772, PubMed:11555828, PubMed:12865317, PubMed:14559847, PubMed:15373842, PubMed:15764715, PubMed:19965576, PubMed:20702771, PubMed:21490593, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:12865317, PubMed:14559847, PubMed:15373842, PubMed:15764715, PubMed:21490593, PubMed:21576599, PubMed:2732228). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2, as well as D-ring hydroxylated E1 and E2 at the C-16 position (PubMed:11555828, PubMed:12865317, PubMed:14559847). Plays a role in the metabolism of androgens, particularly in oxidative deactivation of testosterone (PubMed:15373842, PubMed:15764715, PubMed:22773874, PubMed:2732228). Metabolizes testosterone to less biologically active 2beta- and 6beta-hydroxytestosterones (PubMed:15373842, PubMed:15764715, PubMed:2732228). Contributes to the formation of hydroxycholesterols (oxysterols), particularly A-ring hydroxylated cholesterol at the C-4beta position, and side chain hydroxylated cholesterol at the C-25 position, likely contributing to cholesterol degradation and bile acid biosynthesis (PubMed:21576599). Catalyzes bisallylic hydroxylation of polyunsaturated fatty acids (PUFA) (PubMed:9435160). Catalyzes the epoxidation of double bonds of PUFA with a preference for the last double bond (PubMed:19965576). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed:20702771). Plays a role in the metabolism of retinoids. Displays high catalytic activity for oxidation of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA) (PubMed:10681376). Further metabolizes atRA toward 4-hydroxyretinoate and may play a role in hepatic atRA clearance (PubMed:11093772). Responsible for oxidative metabolism of xenobiotics. Acts as a 2-exo-monooxygenase for plant lipid 1,8-cineole (eucalyptol) (PubMed:11159812). Metabolizes the majority of the administered drugs. Catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole (PubMed:10759686). Hydroxylates antimalarial drug quinine (PubMed:8968357). Acts as a 1,4-cineole 2-exo-monooxygenase (PubMed:11695850). Also involved in vitamin D catabolism and calcium homeostasis. Catalyzes the inactivation of the active hormone calcitriol (1-alpha,25-dihydroxyvitamin D(3)) (PubMed:29461981)
- Specific Function
- 1,8-cineole 2-exo-monooxygenase activity
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Wenk M, Todesco L, Krahenbuhl S: Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol. 2004 Apr;57(4):495-9. [Article]
- Hokkanen J, Tolonen A, Mattila S, Turpeinen M: Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomes. Eur J Pharm Sci. 2011 Feb 14;42(3):273-84. doi: 10.1016/j.ejps.2010.12.002. Epub 2010 Dec 17. [Article]
- Klotz U: Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist. Arzneimittelforschung. 2002;52(3):155-61. doi: 10.1055/s-0031-1299873. [Article]
- FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Inhibitor
- General Function
- A cytochrome P450 monooxygenase involved in the metabolism of fatty acids, steroids and retinoids (PubMed:18698000, PubMed:19965576, PubMed:20972997, PubMed:21289075, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:18698000, PubMed:19965576, PubMed:20972997, PubMed:21289075, PubMed:21576599). Catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) (PubMed:19965576, PubMed:20972997). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 20-hydroxyeicosatetraenoic acid ethanolamide (20-HETE-EA) and 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed:18698000, PubMed:21289075). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed:21576599). Catalyzes the oxidative transformations of all-trans retinol to all-trans retinal, a precursor for the active form all-trans-retinoic acid (PubMed:10681376). Also involved in the oxidative metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants
- Specific Function
- anandamide 11,12 epoxidase activity
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Hokkanen J, Tolonen A, Mattila S, Turpeinen M: Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomes. Eur J Pharm Sci. 2011 Feb 14;42(3):273-84. doi: 10.1016/j.ejps.2010.12.002. Epub 2010 Dec 17. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- SubstrateInducer
- General Function
- A cytochrome P450 monooxygenase involved in the metabolism of polyunsaturated fatty acids (PUFA) (PubMed:18577768, PubMed:19965576, PubMed:20972997). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:18577768, PubMed:19965576, PubMed:20972997). Catalyzes the hydroxylation of carbon-hydrogen bonds. Hydroxylates PUFA specifically at the omega-1 position (PubMed:18577768). Catalyzes the epoxidation of double bonds of PUFA (PubMed:19965576, PubMed:20972997). Also metabolizes plant monoterpenes such as limonene. Oxygenates (R)- and (S)-limonene to produce carveol and perillyl alcohol (PubMed:11950794). Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine. Hydroxylates fenbendazole at the 4' position (PubMed:23959307)
- Specific Function
- (R)-limonene 6-monooxygenase activity
- Gene Name
- CYP2C19
- Uniprot ID
- P33261
- Uniprot Name
- Cytochrome P450 2C19
- Molecular Weight
- 55944.565 Da
References
- Hokkanen J, Tolonen A, Mattila S, Turpeinen M: Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomes. Eur J Pharm Sci. 2011 Feb 14;42(3):273-84. doi: 10.1016/j.ejps.2010.12.002. Epub 2010 Dec 17. [Article]
- Rahimi R, Abdollahi M: An update on the ability of St. John's wort to affect the metabolism of other drugs. Expert Opin Drug Metab Toxicol. 2012 Jun;8(6):691-708. doi: 10.1517/17425255.2012.680886. [Article]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Translocates drugs and phospholipids across the membrane (PubMed:2897240, PubMed:35970996, PubMed:8898203, PubMed:9038218). Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins (PubMed:8898203). Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells (PubMed:2897240, PubMed:35970996, PubMed:9038218)
- Specific Function
- ABC-type xenobiotic transporter activity
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- ATP-dependent translocase ABCB1
- Molecular Weight
- 141477.255 Da
References
- Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K: St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther. 2000 Dec;68(6):598-604. [Article]
Drug created at June 30, 2007 17:20 / Updated at October 21, 2024 08:50